Related references
Note: Only part of the references are listed.Investigating the binding interactions of galantamine with β-amyloid peptide
Praveen P. N. Rao et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Acetylcholinesterase inhibitors as Alzheimer therapy: From nerve toxins to neuroprotection
Manjinder Singh et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice
Varsha Shukla et al.
FASEB JOURNAL (2013)
Weight loss and Alzheimer's disease: temporal and aetiologic connections
Giuseppe Sergi et al.
PROCEEDINGS OF THE NUTRITION SOCIETY (2013)
Lysosomal NEU1 deficiency affects amyloid precursor protein levels and amyloid-β secretion via deregulated lysosomal exocytosis
Ida Annunziata et al.
NATURE COMMUNICATIONS (2013)
Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's disease
Scott J. Webster et al.
ALZHEIMERS RESEARCH & THERAPY (2013)
Sensorimotor gating and memory deficits in an APP/PS1 double transgenic mouse model of Alzheimer's disease
Hongxing Wang et al.
BEHAVIOURAL BRAIN RESEARCH (2012)
Alzheimer's Disease, Oestrogen and Mitochondria: an Ambiguous Relationship
Amandine Grimm et al.
MOLECULAR NEUROBIOLOGY (2012)
The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease
Sergey Kalinin et al.
NEUROBIOLOGY OF AGING (2012)
Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition
G. Chetelat et al.
NEUROLOGY (2012)
A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
Ronald B. DeMattos et al.
NEURON (2012)
APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD)
R. Lalonde et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2012)
Galantamine and behavior in Alzheimer disease: analysis of four trials
S. Kavanagh et al.
ACTA NEUROLOGICA SCANDINAVICA (2011)
Amyloid-β Associated Cortical Thinning in Clinically Normal Elderly
J. Alex Becker et al.
ANNALS OF NEUROLOGY (2011)
Astrocytes: Implications for Neuroinflammatory Pathogenesis of Alzheimers Disease
Chuanyu Li et al.
Current Alzheimer Research (2011)
Combination Therapy for Alzheimerʼs Disease
Laxeshkumar Patel et al.
DRUGS & AGING (2011)
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
Eric Karran et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain
T. M. Wengenack et al.
NEUROIMAGE (2011)
Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting
Åsa Wallin et al.
Neuropsychiatric Disease and Treatment (2011)
Galantamine for Alzheimer's disease
David Prvulovic et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Identification of Low Molecular Weight Pyroglutamate Aβ Oligomers in Alzheimer Disease A NOVEL TOOL FOR THERAPY AND DIAGNOSIS
Oliver Wirths et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Galantamine-induced Amyloid-β Clearance Mediated via Stimulation of Microglial Nicotinic Acetylcholine Receptors
Kazuyuki Takata et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Memogain is a Galantamine Pro-drug having Dramatically Reduced Adverse Effects and Enhanced Efficacy
Alfred Maelicke et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2010)
Alzheimer's disease: strategies for disease modification
Martin Citron
NATURE REVIEWS DRUG DISCOVERY (2010)
COL25A1 triggers and promotes Alzheimer's disease-like pathology in vivo
Ying Tong et al.
NEUROGENETICS (2010)
Galantamine inhibits β-amyloid aggregation and cytotoxicity
Balpreet Matharu et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2009)
Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model
Ryoichi Kimura et al.
NEUROBIOLOGY OF DISEASE (2009)
Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques
Robert M. Koffie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease-like pathology
Stephan Schilling et al.
NATURE MEDICINE (2008)
An update on the pharmacology of galantamine
Mercedes Villarroya et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice
Masuo Ohno et al.
NEUROBIOLOGY OF DISEASE (2007)
Gender dependent APP processing in a transgenic mouse model of Alzheimer's disease
S. Schaefer et al.
JOURNAL OF NEURAL TRANSMISSION (2007)
Nicotinic component of galantamine in the regulation of amyloid precursor protein processing
Silvia C. Lenzken et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2007)
Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations:: Potential factors in amyloid plaque formation
Holly Oakley et al.
JOURNAL OF NEUROSCIENCE (2006)
Sensory gating deficit assessed by P50/Pb middle latency event related potential in Alzheimer's disease
Iacopo Cancelli et al.
JOURNAL OF CLINICAL NEUROPHYSIOLOGY (2006)
Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APPswe) transgenic mice
C Unger et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease
JS Jacobsen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1
M Ohno et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2006)
Acute γ-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease
TA Comery et al.
JOURNAL OF NEUROSCIENCE (2005)
Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy
TL Spires et al.
JOURNAL OF NEUROSCIENCE (2005)
Strategies for disease modification in Alzheimer's disease
M Citron
NATURE REVIEWS NEUROSCIENCE (2004)
Learning-induced arg 3.1/arc mRNA expression in the mouse brain
M Montag-Sallaz et al.
LEARNING & MEMORY (2003)
Severe cognitive and motor coordination deficits in tenascin-R-deficient mice
M Montag-Sallaz et al.
GENES BRAIN AND BEHAVIOR (2003)
Misguided axonal projections, neural cell adhesion molecule 180 mRNA upregulation, and altered behavior in mice deficient for the close homolog of L1
M Montag-Sallaz et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Comparative analysis of an improved thioflavin-S stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections
AY Sun et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2002)
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
J Lewis et al.
SCIENCE (2001)
Sensory gating deficit expressed by a disturbed suppression of the P50 event-related potential in patients with Alzheimer's disease
F Jessen et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
Augmented senile plaque load in aged female β-amyloid precursor protein-transgenic mice
MJ Callahan et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease
A Maelicke et al.
BIOLOGICAL PSYCHIATRY (2001)
Share Paper
